0.25 CME/CE Credit
Treating Children and Adolescents with Obesity—Understanding the New AAP Clinical Practice Guidelines - Frankly Speaking Ep 325Guest: Susan Feeney, DNP, FNP-BC, NP-C
Music Credit: Richard Onorato
Obesity in children and adolescents is a complex and very often chronic condition. Besides encouraging healthy eating and increasing activity—both excellent behavioral measures—healthcare providers did not have a clear, evidence-based plan for managing this chronic condition until recently. In January, the AAP published its long-awaited new, evidence-based guidelines for the evaluation and treatment of children and adolescents with obesity. Greatly anticipated, it did, however, create some controversy. Please join us as we discuss the new guidelines, the evidence that it is based on, and how it may change practice.
Episode Reference and Resource Links:
- The American Academy of Pediatrics. Clinical Practice Guideline. S. E. Hampl. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. January 9, 2023. Pediatrics e2022060640. https://doi.org/10.1542/peds.2022-060640
- The American Academy of Pediatrics. S. E. Hampl. Executive Summary: Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity, January 9, 2023. Pediatrics e2022060641.https://doi.org/10.1542/peds.2022-060641; https://publications.aap.org/pediatrics/article/doi/10.1542/peds.2022-060641/190440/Executive-Summary-Clinical-Practice-Guideline-for?autologincheck=redirected
- AAP News release https://www.aap.org/en/news-room/news-releases/aap/2022/american-academy-of-pediatrics-issues-its-first-comprehensive-guideline-on-evaluating-treating-children-and-adolescents-with-obesity/
- The American Academy of Pediatrics Technical report; January 9, 2023. Appraisal of Clinical Care Practices for Child Obesity Treatment. Part I: Interventions. Pediatrics (2023) 151 (2): e2022060642.; https://doi.org/10.1542/peds.2022-060642
- The American Academy of Pediatrics Technical report; January 9, 2023. Appraisal of Clinical Care Practices for Child Obesity Treatment. Part II: Comorbidities. Pediatrics (2023) 151 (2): e2022060643. https://doi.org/10.1542/peds.2022-060643
Already listened on another platform?
- Discuss the new AAP Clinical Practice Guidelines for evaluating and treating children and adolescents with obesity
- Apply these evidence-based guidelines to the care of children, adolescents, and their families
Frank J. Domino, MD
Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA
Susan Feeney, DNP, FNP-BC, NP-C
Assistant Professor and Coordinator of the Family Nurse Practitioner Track
Frank J. Domino, MD: Has disclosed no relevant financial relationships.
Susan Feeney, DNP, FNP-BC, NP-C: Has disclosed no relevant financial relationships.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
AMA PRA Category 1 Credits
Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions for Obtaining Credit
Supporters and Partners
Commercial Supporter Here
Education Partner here
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients. Data, indications, and guidelines presented in this activity are current as of the activity release date and they are subject to change as new information is published.
Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.
Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email firstname.lastname@example.org or call (877) 477-4633.